Literature DB >> 6203672

Antisera to human renin normalize renin-dependent hypertension in the monkey: therapeutic implications.

E E Slater, P Corvol, J Menard, J Burton, L H Hartley.   

Abstract

Polyclonal antisera raised against pure human renin normalize renin-dependent blood pressure elevation in the monkey (M. fascicularis). In vitro, comparable inhibition of either human or monkey plasma renin by the antisera was demonstrated. In vivo, intravenous infusion of 2 ml of antisera did not change mean arterial pressure of salt-repleted monkeys, however, its administration to salt-depleted monkeys with elevated plasma renin activity lowered mean arterial pressure 10 Torr. A 25 Torr rise in mean arterial pressure and increase in plasma renin activity occurred promptly after inflation of a suprarenal aortic cuff in conscious uninephrectomized monkeys. Administration of 2 ml of antisera to these monkeys normalized mean pressure, which was reduced by an additional 10 Torr if the animals were previously salt-depleted. Maximal hypotension occurred within 1 hour and was sustained for approximately 10 hours. Because of the differing specificities of polyclonal antisera, sera raised in two laboratories against human renin purified from different sources were employed. Identical results were obtained. This is the first demonstration of the use of antisera to inhibit endogenous renin activity in primates and predicts the in vivo efficacy of renin antisera as experimental, diagnostic and therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203672     DOI: 10.3109/10641968409044047

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  2 in total

Review 1.  Renin inhibitors as possible antihypertensive agents.

Authors:  K G Hofbauer; J M Wood
Journal:  Klin Wochenschr       Date:  1988-09-15

Review 2.  Hypertension Vaccine may be a boon to millions in developing world.

Authors:  Mohan Bairwa; Manju Pilania; Vivek Gupta; Kapil Yadav
Journal:  Hum Vaccin Immunother       Date:  2013-12-23       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.